IL-21 antibodies and methods of making or using the antibodies
US9394362B2 · kind B2 · utility
0Cited by
4References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2015 |
| Grant date | Jul 19, 2016 |
| Priority date | — |
| Expiry date | Mar 13, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.